[Anti-angiogenic therapy in breast cancer].
Angiogenesis is important for tumor growth and breast cancer development. Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor(VEGF)-A, and it is the only anti-angiogenic agent approved for breast cancer treatment in Japan. In this article, we discuss the efficacy, tolerability, and potential future refinements for the use of bevacizumab.